Published in Clinical Oncology Week, October 20th, 2008
"We show that BAP1 fulfills mother criterion of a genuine tumor suppressor because cancer-associated BAP1 mutants are deficient in deubiquitinating activity. We show for the first time that. one of the two predicted nuclear targeting motifs is required for nuclear localization of BAP1 and that a truncation mutant,...
Want to see the full article?
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of Clinical Oncology Week
NewsRx also is available at LexisNexis, Gale, ProQuest, Factiva, Dialog, Thomson Reuters, NewsEdge, and Dow Jones.